GlassScriptPhysician profile
Mario Skugor
NPI 1386734622
$44,856.96
in general payments reported to CMS, 2019-2025
12 companies · $43K in 2025
The $43K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $96.69 · 2021: $524 · 2022: $247 · 2023: $205 · 2024: $53.20 · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Travel and Lodging: $3,477 · Food and Beverage: $947.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39,294.00 |
| Travel and Lodging | $3,477.39 |
| Food and Beverage | $947.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $43,390.98 | 2025 | Yorvipath |
| Novo Nordisk INC | $494.63 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $492.86 | 2019-2022 | |
| Horizon Therapeutics Plc | $124.99 | 2023 | Tepezza |
| Merck Sharp & Dohme LLC | $90.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.91 | 2019-2022 | |
| Lilly USA, LLC | $45.86 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $40.46 | 2023 | |
| Xeris Pharmaceuticals, INC. | $36.33 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.42 | 2022 | |
| Medtronic, INC. | $22.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mario Skugor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.